Testagen
Evidence: D+Hormone / Fertility
Evidence Snapshot
Regulatory Context
Do not present KEDG as testosterone replacement, fertility treatment, or an approved endocrine drug.
Research Takeaway
Testagen is KEDG, Lys-Glu-Asp-Gly.
See all 7 evidence claims →Quick Summary
Testagen is the tetrapeptide Lys-Glu-Asp-Gly (KEDG), studied for cellular/nuclear penetration and older endocrine/reproductive preclinical literature. Its name should not be interpreted as evidence it raises testosterone.
Mechanism & Research Overview
Ultrashort-peptide studies report cellular/nuclear penetration and nucleic-acid interactions for KEDG-class peptides.
Evidence Claims
Individual scientific statements drawn from the sources cited below, each shown with the specific evidence boundary that statement does not establish.
Supported
Testagen is KEDG, Lys-Glu-Asp-Gly.
Supported
Ultrashort-peptide studies report cellular/nuclear penetration and nucleic-acid interactions for KEDG-class peptides.
Sources: Penetration of short fluorescence-labeled peptides into the nucleus in HeLa cells and in vitro specific interaction of the peptides with deoxyribooligonucleotides and DNA; Peptide Regulation of Gene Expression: A Systematic Review
Supported
Older endocrine/reproductive and thyroid-related experimental literature reports biological effects, but the body of evidence is limited.
Supported
A 2025 materials-science study confirms KEDG/Testagen usage in an adsorption-on-copper context; this is identity/materials-chemistry evidence only, not therapeutic efficacy.
Sources: 2025 materials-science study of KEDG/Testagen adsorption on copper
Supported
No strong replicated clinical trial program was identified establishing testosterone, fertility, or endocrine benefits.
Sources: MitoCore Batch 9 human-clinical-evidence literature search audit
Supported
The name "Testagen" must not be interpreted as evidence that the peptide increases testosterone in humans.
Sources: MitoCore Batch 9 human-clinical-evidence literature search audit
Supported
Do not present KEDG as testosterone replacement, fertility treatment, or an approved endocrine drug.
Sources: MitoCore Batch 9 regulatory search: FDA approval status and ClinicalTrials.gov registration check
Safety & Evidence Limitations
Considerations reported in the sources cited on this page — not a complete list of every possible risk, and not medical advice.
Safety Consideration
The name "Testagen" must not be interpreted as evidence that the peptide increases testosterone in humans.Safety Consideration
No strong replicated clinical trial program was identified establishing testosterone, fertility, or endocrine benefits.Safety Consideration
A substantial portion of the Testagen literature comes from overlapping investigators and institutions within the Khavinson/St. Petersburg bioregulator research program. This concentration limits independent replication and generalizability; repeated publications from the same research lineage should not be interpreted as equivalent to independent multicenter replication.
Research Areas Being Studied
Research areas discussed on this page reflect the Hormone / Fertility category and the sources cited below.
Findings Reported in Studies
Educational summary only — reported in cited studies, not a claim of proven benefit.
No Human Study Findings Listed Yet
See preclinical, regulatory, and review sources below.
Study Tables by Evidence Type
Human Studies & Clinical Data
No Human Studies & Clinical Data Listed Yet
This section will be updated as sources are added.
Animal / Cell / Preclinical Data
| Title | Year | Population / Model | Dose / Duration / Finding | Safety Notes | Source |
|---|---|---|---|---|---|
| 2025 materials-science study of KEDG/Testagen adsorption on copper | 2025 | Materials-science study of KEDG/Testagen adsorption behavior on copper surfaces. Identity/materials-chemistry evidence only -- NOT therapeutic efficacy evidence. | Not applicable to human therapeutic claims; analytical/materials-chemistry context only. | ||
| Penetration of short fluorescence-labeled peptides into the nucleus in HeLa cells and in vitro specific interaction of the peptides with deoxyribooligonucleotides and DNA | 2011 | The study included fluorescently labeled Pinealon (Glu-Asp-Arg) and reported cellular or nuclear penetration and interactions with nucleic-acid targets in vitro. | |||
| Hypophyseal KEDG-related endocrine/aging study | Older endocrine/reproductive and hypophyseal-related experimental literature reporting biological effects associated with KEDG; the body of evidence is limited. |
Regulatory Documents & Official Trial Registries
| Title | Year | Population / Model | Dose / Duration / Finding | Safety Notes | Source |
|---|---|---|---|---|---|
| MitoCore Batch 9 regulatory search: FDA approval status and ClinicalTrials.gov registration check | 2026 | Direct search performed 2026-08-17 for FDA drug-approval status and ClinicalTrials.gov interventional-trial registration for PNC-27, Pancragen, Bronchogen, Testagen, Chonluten, Prostamax, Ovagen, and N-Acetyl Epitalon Amidate (Ac-AEDG-NH2), including known aliases and sequence names. No FDA-approved drug product was identified for any of the eight compounds. No registered ClinicalTrials.gov interventional trial was identified for any of the eight compounds. All eight are marketed exclusively through peptide/research-chemical vendors as research-use-only products, not as approved medicines. Absence from these searches is not itself a formal FDA determination and does not establish safety or ineffectiveness -- it establishes only that no approval or registered trial was located in this search pass. |
Review Articles / Secondary Sources
| Title | Year | Population / Model | Dose / Duration / Finding | Safety Notes | Source |
|---|---|---|---|---|---|
| Peptide Regulation of Gene Expression: A Systematic Review | 2021 | The review identifies AED as Cartalax and summarizes short-peptide gene-regulatory work. The literature is predominantly mechanistic/preclinical and cannot establish clinical disease-modifying efficacy. | PMCID: PMC8619776. STRUCTURAL BLOCKER: frozen scope also includes Cartalax/AED, Vilon/Lys-Glu, and Livagen/KEDA, none of which have a Peptide document yet; schema's peptideNameFallback field is a single string and cannot hold more than one missing-subject name, so only the one already-existing subject (Vesugen) is linked here. See Stage 2 report. |
Anecdotal Reported Patterns — Not Medical Advice
Anecdotal Reported Patterns — Not Medical Advice
Reported dosing patterns are included for educational context only. They are self-reported, unverified, not medical advice, and not instructions for human use. Community-submitted patterns are not yet available in this Phase 1 prototype; this section is a placeholder reserved for moderated, aggregated community data.
Lab Markers to Discuss With a Clinician
Educational topics only — not self-monitoring instructions.
FAQ
Disclaimer
Educational information only. This page summarizes published research and does not provide medical advice, a recommendation, or instructions for human use.
Educational use only. This content is provided for informational and research-summary purposes only. It is not medical advice, not a treatment recommendation, not a dosing guide, and not a substitute for care from a licensed medical professional. Nothing here is intended to diagnose, treat, cure, prevent, or mitigate disease. Reported dosing patterns, when shown elsewhere on the site, must be labeled either as Study / Trial Dosing or Anecdotal Reported Patterns — Not Medical Advice. Community reports are self-reported, unverified, and not scientific proof.
Community-reported experiences, once enabled, must be displayed only as moderated, anonymized, or aggregated data. They are anecdotal, self-reported, unverified, and should never be presented as proof of safety, efficacy, or expected results.
Content status: Content pending review. Last updated 2026-08-17.
Follow research updates for Testagen
Get notified in your MitoCore account when this profile is updated, a new study is added, or its evidence grade changes.
Get updates when new studies or safety notes are added for this peptide.
Get educational updates on new studies, evidence-grade changes, and safety notes. Educational content only — not medical advice.